Recruiting
Phase 2
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
About this study
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
- Condition
- Metastatic Colorectal Cancer
- Tested
- Liposomal irinotecan, TAS102, Bevacizumab
- Sponsor
- University of Wisconsin, Madison
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Metastatic Colorectal Cancer
- Patients must be ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance must be 0 or 1.
- Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable.
- The cancer must be mismatch repair proficient.
- Patients must have had prior treatment with 5-fluorouracil, oxaliplatin, irinotecan containing regimens. If RAS wild-type must have received prior anti-EGFR therapy with either cetuximab or panitumumab. If RAS wild-type and HER2 positive then must have had a prior HER2 targeted therapy.
Exclusion 5
- Uncontrolled concurrent medical illness that would not allow for the completion of the planned therapy.
- Patients whose cancers possess BRAF V600 mutations are excluded.
- Patients must stop the use of strong inducers/inhibitors of CYP3A4 at least 2 weeks before initiating therapy.
- Patients must not have mismatch repair deficient or microsatellite instability high cancers.
- Patients must not have received prior TAS102.
Where
1 site, 1 recruiting
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Contact
-
Cancer Connect
800-622-8922 clinicaltrials@cancer.wisc.edu
Potential match only. Final eligibility is determined by the study team.